Digitally Enhanced Smoking Cessation for High Risk Smokers
This is a research study, is testing a program to improve lung health through smoking cessation and providing education around lung screening. In this research study involves Studying the Enhanced Smoking Cessation Approaches to Promote Empowerment (ESCAPE) program compared to usual care. The ESCAPE program was developed help women with HIV quit smoking. Women in the ESCAPE program quit smoking and stayed quit for longer (up to 3 months). For this study, investigators have added a lung screening to the ESCAPE program and want to test if this will improve lung health through increasing quit rates and lung screening. .
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Dec 19, 2025 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Dana-Farber Cancer Institute
- Interventions being studied
- Other: Escape; Other: Standard Care
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- 55 to 77 years of age
- No previous history of lung cancer
- ECOG performance status \< 2
- ≥ 30 pack year smoking history
- Smoke ≥ 5 cigarettes/day
- Own a mobile phone with access to a video call application
- Has a primary care provider (PCP)
- Provide contact information for the PCP
- Active health insurance
- Has not had LDCT screening
- English speaking
- Can complete an interview
- Hospitalization for severe mental illness within the last year.
- The following special populations will not be included
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Brigham and Women's HospitalBoston, Massachusetts
- Dana Farber Cancer InstituteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 19, 2025. Always confirm current availability with the study team.